Xtant Medical Holdings Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

XTNT$0.28-3.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Changes in Stockholders’ Equity

(In thousands, except number of shares and par value)

Common Stock · Additional Paid-In- · Accumulated Other Comprehensive · Accumulated · Total Stockholders’
	Shares	Total	Capital	Loss	Deficit	Equity
Balance at December 31, 2021	87,068,980	$—	$266,068	—	$(235,185)	$30,883
Private placement of common stock, net of issuance costs of $436	20,305,429	—	7,681	—	—	7,681
Warrants issued in connection with the private placement	—	—	1,628	—	—	1,628
Common stock issued on vesting of restricted stock units	1,500,394	—	—	—	—	—
Stock-based compensation	—	—	2,464	—	—	2,464
Net loss	—	—	—	—	(8,485)	(8,485)
Balance at December 31, 2022	108,874,803	$—	$277,841	—	$(243,670)	$34,171
Private placement of common stock, net of issuance costs of $175	20,000,000	—	14,011	—	—	14,011
Common stock issued on vesting of restricted stock units	1,536,251	—	—	—	—	—
Withholding on common stock upon vesting of restricted stock units	(231,023)	—	(261)	—	—	(261)
Stock-based compensation	—	—	2,739	—	—	2,739
Foreign currency translation adjustment	—	—	—	29	—	29
Net income	—	—	—	—	660	660
Balance at December 31, 2023	130,180,031	$—	$294,330	$29	$(243,010)	$51,349

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.